MHRA approves licence extension for cystic fibrosis (CF) treatment Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor

This regimen is now licensed for treatment of CF in all patients aged ≥12 years, who have ≥1 F508del mutation in CFTR gene. Approval was supported by results of 3 phase III studies. Long-term reimbursement agreements means eligible patients will have access to this treatment

Source:

PharmaTimes